Human melanoma cells do not express Fas (Apo-1/CD95) ligand

Cancer Research

Volumn 59, Issue 1, 1999, Pages 59-62

  Chappell, Dale B ^a   Zaks, Tal Z ^b   Rosenberg, Steven A ^b   Restifo, Nicholas P ^b  

^a HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAS LIGAND;

ARTICLE; ARTIFACT REDUCTION; CANCER CELL CULTURE; CELL KILLING; HUMAN; HUMAN CELL; INFLAMMATION; LIGAND BINDING; MELANOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE SPECIFICITY; TUMOR ESCAPE;

FAS LIGAND PROTEIN; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MELANOMA; MEMBRANE GLYCOPROTEINS; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 0032919157     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Hellstrom, I., and Hellstrom, K. E. Tumor vaccines - a reality at last? J. Immunother., 21: 119-126, 1998.
2. Mitchell, M. S. Immunotherapy of melanoma. J. Invest. Dermatol. Symp. Proc., 1: 215-218, 1996.
3. Fenton, R. G., and Longo, D. L. Danger versus tolerance: paradigms for future studies of tumor-specific cytotoxic T lymphocytes. J. Natl. Cancer Inst. (Bethesda), 89: 272-275, 1997.
4. Rosenherg, S. A., Yang, J. C. Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., Reslifo, N. P., Dudley, M. E., Schwarz, S. L., Spiess, P. J., Wunderlich, J. R., Parkhurst, M. R., Kawakami, Y., Seipp, C. A., Einhorn, J. H., and White, D. E. Immunologic and therapeutic evaluation of a synthetic peplide vaccine for the treatment of patients with metastatic melanoma. Nat. Med., 4: 321-327, 1998.
5. Correa, M. R., Ochoa, A. C., Ghosh, P., Mizoguchi, H., Harvey, L., and Longo, D. L. Sequential development of structural and functional alterations in T cells from tumor-bearing mice. J. Immunol., 158: 5292-5296, 1997.
6. Vaux, D. L. Immunology. Ways around rejection (Retraction of Nature (Lond.), 377: 576-577, 1995). Nature (Lond.), 394: 133, 1998.
7. Vaux, D. L. Immunology. Ways around rejection (Retraction of Nature (Lond.), 377: 576-577, 1995). Nature (Lond.), 394: 133, 1998.
8. Hahne, M., Rimoldi, D., Schroter, M., Romero, P., Schreier, M., French, L. E., Schneider, P., Bornand, T., Fontana, A., Lienard, D., Cerottini, J., and Tschopp, J. Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor immune escape. Science (Washington DC), 274: 1363-1366, 1996.
9. Rivoltini, L., Radrizzani, M., Accornero, P., Squarcina, P., Chiodoni, C, Mazzocchi, A., Castelli, C., Tarsini, P., Viggiano, V., Belli, F., Colombo, M. P., and Parmiani, G. Human melanoma-reactive CD4+ and CD8+ CTL clones resist Fas ligand-induced apoptosis and use Fas/Fas ligand-independent mechanisms for tumor killing. J. Immunol., 161: 1220-1230, 1998.
10. Smith, D., Sieg, S., and Kaplan, D. Technical note: aberrant detection of cell surface Fas ligand with anti-peptids antibodies. J. Immunol., 160: 4159-4160, 1998.
11. Fiedler, P., Schaetzlein, C. E., and Eibel, H. Constitutive expression of FasL in thyrocytes Science (Washington DC), 279: 2015a, 1998.
12. O'Connell, J., O'Sullivan, G. C. Collins, J. K., and Shanahan, F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J. Exp. Med., 184: 1075-1082, 1996.
13. Sarin, A., Williams, M. S., Alexander-Miller, M. A., Berzofsky, J. A., Zacharchuk, C. M., and Henkart, P. A. Target cell lysis by CTL granule exocytosis is independent of ICE/Ced-3 family proteases. Immunity, 6: 209-215, 1997.
14. Shiraki, K., Tsuji, N., Shioda, T., Isselbacher, K. J., and Takahashi, H. Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. Proc. Natl. Acad. Sci USA, 94: 6420-6425, 1997.
15. Arai, H., Gordon, D., Nabel, E. G., and Nabel, G. J. Gene transfer of Fas ligand induces tumor regression in vivo. Proc. Natl. Acad. Sci USA, 94: 13862-13867, 1997.
16. Bohm, C., Hanski, M. L., Gratchev, A., Mann, B., Mover, M. P., Riecken, E. O., and Hanski, C. A modification of the JAM test is necessary for a correct determination of apoptosis induced by FasL+ adherent tumor cells, J. Immunol. Methods, 217: 71-78, 1998.
17. Miller, D. K. The role of the caspase family of cysteine proteases in apoptosis. Semin. Immunol., 9: 35-49, 1997.
18. Kang, S. M., Schneider, D. B., Lin, Z., Hanahan, D., Dichek, D. A., Stock, P. G., and Baekkeskov, S. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat. Med., 3: 738-743, 1997.
19. Kang, S. M., Lin, Z., Ascher, N. L., and Stock, P. G. Fas ligand expression on islets as well as multiple cell lines results in accelerated neutrophilic rejection. Transplant. Proc., 30: 538, 1998.
20. Allison, J., Georgiou, H. M., Strasser, A., and Vaux, D. L. Transgenic expression of CD95 ligand on islet β cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts. Proc. Natl. Acad. Sci. USA, 94: 3943-3947, 1997.
21. Kang, S. M., Hoffmann, A., Le, D., Springer, M. L., Stock, P. G., and Blau, H. M. Immune response and myoblasts that express Fas ligand. Science (Washington DC), 278: 1322-1324, 1997.
22. Ehl, S., Hoffmann-Rohrer, U., Nagata, S., Hengartner, H., and Zinkemagel, R. Different susceptibility of cytotoxic T cells to CD95 (Fas/Apo-1) ligand-mediated cell death after activation in vitro versos in vivo. J. Immunol., 156: 2357-2360, 1996.
23. Seino, K., Kayagaki, N., Okumura, K., and Yagita, H. Antitumor effect of locally produced CD95 ligand. Nat. Med., 3: 165-170, 1997.
24. Chen, J-J., Sun, Y., and Nabel, G. J. Regulation of the proinflammatory effects of Fas ligand (CD95L). Science (Washington DC), 281: 1714-1717, 1998.